Research programme: anticancer antibodies - Genentech

Drug Profile

Research programme: anticancer antibodies - Genentech

Alternative Names: Anti-EphA2 antibody; anti-TenB2 ADC; anti-TenB2 antibody drug conjugate; TAC - Genentech; Thio-Mab anti-TenB2 ADC; ThioMab drug conjugates; THIOMAB™ antibiotic conjugate - Genentech

Latest Information Update: 22 Apr 2010

Price : $50

At a glance

  • Originator Genentech
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 21 Apr 2010 The programme is still in active development
  • 08 Nov 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the Cancer pharmacodynamics section
  • 09 May 2005 Preclinical trials in Cancer in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top